Adaptimmune Therapeutics (ADAP) Narrows Q1 Loss

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of $-0.00, versus (GBP0.01) reported last year. Revenue for the quarter came in at GBP2.6 million, versus GBP944 thousand reported last year.

Adaptimmune is reiterating its cash burn guidance. For the six months ending December 31, 2015, the Company expects its cash burn to be between $20 and $30 million, excluding cash burn associated with new business development activities. For the full year 2016, the Company expects its cash burn to be between $80 and $100 million, excluding cash burn associated with new business development activities, and expects its liquidity position at December 31, 2016, including cash, cash equivalents, and short term deposits, to be at least $150 million. The mix of cash and cash equivalents and short-term deposits is not provided as guidance.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
• Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook
• Sysco raises mid-term targets, unveils $500M AI efficiency program